Kenvue Inc. (KVUE)
| Market Cap | 37.11B +35.1% |
| Revenue (ttm) | 15.53B +3.5% |
| Net Income | 1.69B +17.9% |
| EPS | 0.88 +17.7% |
| Shares Out | 1.92B |
| PE Ratio | 21.94 |
| Forward PE | 15.90 |
| Dividend | $0.84 (4.35%) |
| Ex-Dividend Date | Sep 21, 2026 |
| Volume | 66,596,062 |
| Open | 19.99 |
| Previous Close | 19.56 |
| Day's Range | 19.20 - 20.00 |
| 52-Week Range | 14.02 - 20.13 |
| Beta | 0.45 |
| Analysts | Hold |
| Price Target | 19.50 (+0.98%) |
| Earnings Date | Oct 30, 2026 |
About KVUE
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral a... [Read more]
Financial Performance
In 2025, Kenvue's revenue was $15.12 billion, a decrease of -2.14% compared to the previous year's $15.46 billion. Earnings were $1.47 billion, an increase of 42.72%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for KVUE stock is "Hold." The 12-month stock price target is $19.5, which is an increase of 0.98% from the latest price.
News
Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, N...
Okta to replace Kenvue in S&P 500 at open on 11/4
S&P 500 constituent Kimberly-Clark (KMB) is acquiring Kenvue (KVUE) in a deal expected to be completed soon, pending final closing conditions.
Kenvue Earnings release: Q3 2026
Kenvue released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
Kenvue Quarterly report: Q3 2026
Kenvue has published its Q3 2026 quarterly earnings report on October 30, 2026.
Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
Kenvue reported higher profit and revenue as it works to turn around its business ahead of its $40 billion acquisition by consumer-products company Kimberly-Clark.
Kenvue reports Q3 adjusted EPS 29c, consensus 29c
Reports Q3 revenue $3.89B, consensus $3.86B. “We are pleased to have delivered our fourth consecutive quarter of net and organic sales growth, with strong performance in Self Care and Essential…
Kenvue Reports Third Quarter 2026 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal third quarter ended September 27, 2026. “We are pleased to have delivered our fourth consecutiv...
Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes
DALLAS, Oct. 27, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the extension of the expiration date of the offers to exchange (each an "Exchange Offe...
Kenvue to Announce Third Quarter 2026 Results on October 30, 2026
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before the market opens on October 30, 2026. Due to the pending transaction with Kimberly...
Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.
Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up
The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia...
EC approves Kimberly-Clark acquisition of Kenvue, subject to conditions
The European Commission has approved, under the EU Merger Regulation, the proposed acquisition by Kimberly-Clark (KMB) of Kenvue (KVUE), the commission announced. The approval is conditional upon full...
Kimberly-Clark Announces Successful Consent Solicitations for Kenvue Notes and Amendment to Terms of Exchange Offers
DALLAS, Oct. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today that the requisite number of consents have been received to adopt certain proposed ame...
Kimberly-Clark announces planned executive transitions
Kimberly-Clark (KMB) announced planned executive transitions and updates to the future leadership team for the company upon completion of its pending acquisition of Kenvue (KVUE), which is expected in...
Kimberly-Clark Announces Planned Executive Transitions and Updates to Post-Closing Leadership Team
Russ Torres to Depart Kimberly-Clark for External CEO Role Carlos De Jesus to be Appointed as President, North America and Leonardo Curado to be Appointed as President, EMEA After Kenvue Acquisition D...
Kimberly-Clark Corporation Announces Commencement of Exchange Offers and Consent Solicitations for Kenvue Notes
DALLAS, Sept. 28, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("A...
Burning a Hole in My Pocket
I'm talking about the cash I have sitting here that I desperately want to get into the market. Earlier this year, I got a chunk of money from selling a house.
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal
Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.
Kimberly-Clark readying asset sales for Kenvue deal EU approval, Reuters says
Kimberly-Clark (KMB) is preparing concessions to address EU antitrust concerns over its roughly $40B acquisition of Kenvue (KVUE), potentially clearing the way for regulatory approval after the Europe...
Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
Kimberly-Clark is readying concessions to address EU antitrust concerns about its bid for Tylenol maker Kenvue that could help it win approval for the $40 billion deal after a preliminary review,...
My Favorite Consumer Staples Play Right Now
Owning consumer staples stocks is an absolute must in a dividend investing strategy. Most people turn to dividend stocks for two reasons — to generate income or to put the magic of compounding to work...
Kenvue Declares Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is paya...
Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters
Female reproductive organ development may be impacted by a mother's use of Tylenol during pregnancy, according to researchers who emphasize that their study does not prove the pain medicine is to bl...
Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands ...
Kimberly-Clark seeking EU approval for $40B Kenvue takeover, Reuters reports
Kimberly-Clark (KMB) has asked EU regulators permission for its proposed $40B takeover of Kenvue (KVUE), Reuters’ Bart Meijer reports. Kimberly-Clark announced the takeover in November 2025, and the d...